REGN
HealthcareRegeneron Pharmaceuticals, Inc. · Biotechnology · $76B
What is Regeneron Pharmaceuticals, Inc.?
Regeneron Pharmaceuticals is a large-cap biopharmaceutical company headquartered in Tarrytown, New York, focused on discovering and commercializing medicines for serious diseases worldwide.
Regeneron generates revenue by developing and selling prescription medicines across multiple therapeutic areas, including eye disease, inflammatory conditions, cancer, and cardiovascular disease. The company partners with major pharmaceutical firms — most notably Sanofi — to co-develop and co-commercialize key products, broadening its commercial reach without bearing all costs alone.
Founded in 1991, Regeneron has grown from a research-stage startup into one of the most recognized names in biotechnology.
- EYLEA (retinal disease treatment)
- Dupixent (atopic dermatitis and asthma)
- Libtayo (skin cancer immunotherapy)
- Praluent (cardiovascular cholesterol management)
Is REGN a Good Stock to Buy?
UQS Score rates REGN as Good overall, reflecting a balanced profile across its five quality pillars.
The Risk pillar stands out as the strongest element of Regeneron's profile, suggesting the company carries relatively low financial and operational risk compared to many biotech peers. Valuation also registers as Good, meaning the stock does not appear significantly stretched on a composite basis.
Growth and Moat both register as Neutral, indicating that near-term expansion and competitive differentiation are areas worth monitoring closely.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does REGN pay dividends?
Yes — Regeneron Pharmaceuticals, Inc. pays a dividend.
Regeneron pays a regular dividend, which is relatively uncommon among large biotech companies. This reflects the company's financial maturity and cash generation capacity. Income-oriented investors may view this as a sign of balance sheet confidence, though the primary investment case remains centered on pipeline and product growth.
When does REGN report earnings?
Regeneron reports earnings on a quarterly cadence, typical for US-listed equities.
Revenue trends have been shaped by the performance of flagship products like Dupixent and EYLEA, alongside ongoing pipeline investments. Results can vary quarter to quarter depending on collaboration revenue from Sanofi and competitive dynamics in key therapeutic areas.
For the most recent quarter's results, see Regeneron's investor relations page at investor.regeneron.com.
REGN Price History
+5.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Regeneron Pharmaceuticals, Inc.?
Based on Regeneron Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Regeneron do?
Regeneron discovers, develops, and sells prescription medicines for conditions including retinal disease, inflammatory disorders, cancer, and cardiovascular disease. It operates both independently and through major collaboration agreements, particularly with Sanofi.
Does REGN pay dividends?
Yes, Regeneron pays a regular dividend. This is notable for a biotech company and reflects its financial maturity. For current dividend details, check Regeneron's investor relations page.
When does REGN report earnings?
Regeneron reports on a quarterly basis, in line with standard US-listed company practice. For exact upcoming dates, visit the company's investor relations page directly.
Is REGN a good stock to buy?
UQS Score rates REGN as Good overall. The Risk pillar is Strong and Valuation is Good, while Growth and Moat are Neutral. Whether it fits your portfolio depends on your own investment goals — the full pillar breakdown is available to Pro members.
Is REGN overvalued?
The UQS Valuation pillar for REGN is rated Good, suggesting the stock is not significantly overpriced on a composite basis relative to its fundamentals. View the complete valuation analysis by signing up for UQS Pro.
What is REGN's market cap bracket?
Regeneron is classified as a large-cap stock, placing it among the more established and financially stable companies in the biopharmaceutical sector.
Who founded Regeneron Pharmaceuticals?
Regeneron was founded in 1991. Founding details, including the names of its founders, are widely available through public sources such as the company's official history page and financial filings.
Is REGN a long-term quality stock?
As a long-term quality indicator, REGN's Good UQS Score — anchored by a Strong Risk rating — suggests a relatively stable foundation. However, Neutral Growth and Moat scores indicate investors should monitor pipeline progress and competitive positioning over time.
Unlock Full REGN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare REGN against sector peers on quality and valuation
- ✓Get the full analyst-style profile in one place
Pro Analysis
REGN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | 17.0 | 0.0 | 46.0 | 0.0 | 36.9 | 0.0 | -48.3 |
| Jul 29, 2026 | 65.3 | 70.0 | 46.0 | 46.4 | 100.0 | 80.1 | -0.6 |
| Jul 25, 2026 | 65.9 | 70.7 | 46.0 | 46.4 | 100.0 | 82.7 | -0.1 |
| Jul 23, 2026 | 66.0 | 70.8 | 46.0 | 46.6 | 100.0 | 83.1 | +0.4 |
| Jul 22, 2026 | 65.6 | 70.3 | 46.0 | 46.6 | 100.0 | 81.4 | 0.0 |
| Jul 21, 2026 | 65.6 | 70.4 | 46.0 | 46.6 | 100.0 | 81.3 | +0.1 |
| Jul 19, 2026 | 65.5 | 70.3 | 46.0 | 46.6 | 100.0 | 80.5 | 0.0 |
| Jul 17, 2026 | 65.5 | 70.3 | 46.0 | 46.8 | 100.0 | 80.5 | +0.1 |
| Jul 16, 2026 | 65.4 | 70.6 | 46.0 | 46.8 | 100.0 | 79.6 | -0.5 |
| Jul 15, 2026 | 65.9 | 70.7 | 46.0 | 46.8 | 100.0 | 82.1 | +0.1 |
REGN — Pillar Breakdown
Quality
— 0.0/100 (25%)Regeneron Pharmaceuticals, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Ability to convert revenue into operating profit.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Regeneron Pharmaceuticals, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Analyst consensus for future revenue growth.
Risk
— 36.9/100 (15%)Regeneron Pharmaceuticals, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Regeneron Pharmaceuticals, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 46/100 (25%)Regeneron Pharmaceuticals, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for REGN.
Score Composition
Financial Data
More Stock Analysis
How is the REGN UQS Score Calculated?
The UQS (Unified Quality Score) for Regeneron Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Regeneron Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Regeneron Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.